Department of Obstetrics & Gynecology, Mansoura University, Egypt.
Acta Obstet Gynecol Scand. 2012 Apr;91(4):489-95. doi: 10.1111/j.1600-0412.2012.01350.x.
To compare the efficacy of aromatase inhibitor vs. gonadotrophin-releasing hormone agonists in treating premenopausal women with uterine adenomyosis.
A prospective randomized controlled study.
A university hospital and a private practice setting.
Thirty-two patients with uterine adenomyosis.
Patients were randomly allocated to receive oral letrozole (2.5 mg/day) or a subcutaneous gonadotropin-releasing hormone agonist (goserelin, 3.6 mg) for 12 weeks. Uterine and adenomyoma volumes were determined at baseline and during treatment at four, eight and 12 weeks.
Measurements were performed at baseline and during treatment at four, eight 8 and 12 weeks, and mean values were calculated. Symptoms at the start and after 12 weeks were evaluated.
No significant differences in the total uterine size between the post treatment uterine volumes in the two groups (20.1, 15.4 and 13.0 cm(3) vs. 21.7, 15.1 and 11.7 cm(3) , at four, eight and 12 weeks, respectively). Total adenomyoma volume decreased by 8.6, 29.7 and 40.9% vs. 5.7, 34.6 and 49.1% after four, eight and 12 weeks of treatment, in group A and B, respectively. Two patients became pregnant in group A during treatment.
Aromatase inhibitors are as effective as gonadotropin-releasing hormone agonists in reducing adenomyoma volume and improving symptoms.
比较芳香化酶抑制剂与促性腺激素释放激素激动剂治疗有子宫腺肌病的绝经前妇女的疗效。
前瞻性随机对照研究。
一所大学医院和一家私人诊所。
32 例子宫腺肌病患者。
患者随机分为口服来曲唑（2.5mg/天）或皮下促性腺激素释放激素激动剂（戈舍瑞林，3.6mg）治疗 12 周。在基线和治疗的第 4、8 和 12 周分别测定子宫和腺肌瘤的体积。
在基线和治疗的第 4、8 和 12 周进行测量，并计算平均值。评估治疗前后的症状。
两组治疗后总子宫大小无显著差异（分别为治疗后 4、8 和 12 周的 20.1、15.4 和 13.0cm3）。总腺肌瘤体积分别减少了 8.6%、29.7%和 40.9%和 5.7%、34.6%和 49.1%。治疗期间，A 组有 2 例患者怀孕。
芳香化酶抑制剂与促性腺激素释放激素激动剂一样有效，可减少腺肌瘤体积并改善症状。
